The rapidly changing treatment landscape of first-line advanced urothelial cancer (aUC) or metastatic urothelial cancer (mUC)

Exploration of Targeted Anti-tumor Therapy, Journal Year: 2024, Volume and Issue: 5(4), P. 971 - 980

Published: July 29, 2024

The landscape of treatment for first-line therapy in advanced urothelial cancer (aUC) and metastatic (mUC) has rapidly changed the last year alone. Maintenance avelumab remains a viable option many patients across globe those who have responded or achieved stable disease after platinum-based chemotherapy. However, recent FDA approvals based on EV-302 enfortumab vedotin (EV) pembrolizumab, as well CheckMate-904 with gemcitabine cisplatin nivolumab (GC+N) followed by maintenance left clinicians complicated decision determining which regimen is most appropriate their individual untreated aUC. This commentary highlights key trials that set standard-of-care front-line aUC suggestions choosing different regimens patient.

Language: Английский

---

Reevaluating immunotherapy’s potential in first-line metastatic urothelial carcinoma

Journal of Chemotherapy, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 2

Published: Aug. 6, 2024

Language: Английский

---

Advancements in the front-line treatment of metastatic urothelial carcinoma

European Urology Focus, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 1, 2024

Language: Английский

---

Meta-analysis of platinum chemotherapy combinations with immunotherapy in metastatic urothelial carcinoma

The Oncologist, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 28, 2024

Abstract The therapeutic landscape for metastatic urothelial carcinoma (mUC) has evolved significantly due to the development of innovative combination treatments, including enfortumab vedotin-pembrolizumab (EVP). Despite these advancements, limited availability EVP means that platinum-based chemotherapy regimens continue serve as primary treatment modality many patients with mUC. We evaluated effect type platinum used in immunotherapy (IO) on outcomes meta-analysis showed cisplatin-gemcitabine plus IO and carboplatin-gemcitabine improve progression-free survival compared platinum-gemcitabine therapy (hazard ratio [HR] = 0.71, 95% CI: 0.62-0.82; P < .0001 HR 0.85, 0.73-0.98; .03, respectively). However, only overall (OS) benefit (HR 0.80, 0.69-0.93; .003). In comparison combination, neither nor combinations demonstrated an objective response rate (ORR) benefit. summary, combining offers significant benefits exact mechanisms—whether cisplatin’s immunomodulatory effects or patient demographic differences—are yet be determined, necessitating further research understand better.

Language: Английский

---

Evolution of front-line immunotherapy for metastatic urothelial cancer

The Lancet Oncology, Journal Year: 2023, Volume and Issue: 25(1), P. 2 - 3

Published: Dec. 12, 2023

Language: Английский

---